Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
98,294,118
-
Total 13F shares
-
15,072,923
-
Share change
-
+2,066,120
-
Total reported value
-
$175,602,356
-
Price per share
-
$11.65
-
Number of holders
-
70
-
Value change
-
+$24,350,253
-
Number of buys
-
31
-
Number of sells
-
24
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) as of Q4 2025
As of 31 Dec 2025,
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,072,923 shares.
The largest 10 holders included
Aberdeen Group plc, VANGUARD GROUP INC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, GOLDMAN SACHS GROUP INC, LEVIN CAPITAL STRATEGIES, L.P., Lisanti Capital Growth, LLC, Empire Life Investments Inc., INVESTMENT MANAGEMENT ASSOCIATES INC /ADV, and ROYCE & ASSOCIATES LP.
This page lists
70
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.